These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26907492)

  • 1. Recurrent glioblastoma: who receives tumor specific treatment and how often?
    Steffens R; Semrau S; Lahmer G; Putz F; Lettmaier S; Eyüpoglu I; Buchfelder M; Fietkau R
    J Neurooncol; 2016 May; 128(1):85-92. PubMed ID: 26907492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of treatment of recurrent glioblastoma multiforme in elderly and/or frail patients.
    Socha J; Kepka L; Ghosh S; Roa W; Kumar N; Sinaika V; Matiello J; Lomidze D; de Castro DG; Hentati D; Fidarova E
    J Neurooncol; 2016 Feb; 126(3):493-8. PubMed ID: 26542030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.
    Straube C; Elpula G; Gempt J; Gerhardt J; Bette S; Zimmer C; Schmidt-Graf F; Meyer B; Combs SE
    Strahlenther Onkol; 2017 Nov; 193(11):897-909. PubMed ID: 28616821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis.
    van Linde ME; Brahm CG; de Witt Hamer PC; Reijneveld JC; Bruynzeel AME; Vandertop WP; van de Ven PM; Wagemakers M; van der Weide HL; Enting RH; Walenkamp AME; Verheul HMW
    J Neurooncol; 2017 Oct; 135(1):183-192. PubMed ID: 28730289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?
    Zanello M; Roux A; Ursu R; Peeters S; Bauchet L; Noel G; Guyotat J; Le Reste PJ; Faillot T; Litre F; Desse N; Emery E; Petit A; Peltier J; Voirin J; Caire F; Barat JL; Vignes JR; Menei P; Langlois O; Dezamis E; Carpentier A; Dam Hieu P; Metellus P; Pallud J;
    J Neurooncol; 2017 Nov; 135(2):285-297. PubMed ID: 28726173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A feasibility study of the Nativis Voyager
    Murphy M; Dowling A; Thien C; Priest E; Morgan Murray D; Kesari S
    CNS Oncol; 2019 Mar; 8(1):CNS31. PubMed ID: 30727742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
    Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
    Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
    Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
    Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma Recurrence Versus Treatment Effect in a Pathology-Documented Series.
    Himes BT; Arnett AL; Merrell KW; Gates MJ; Bhargav AG; Raghunathan A; Brown DA; Burns TC; Parney IF
    Can J Neurol Sci; 2020 Jul; 47(4):525-530. PubMed ID: 32077389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An early feasibility study of the Nativis Voyager
    Cobbs C; McClay E; Duic JP; Nabors LB; Morgan Murray D; Kesari S
    CNS Oncol; 2019 Mar; 8(1):CNS30. PubMed ID: 30547676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields.
    Rulseh AM; Keller J; Klener J; Sroubek J; Dbalý V; Syrůček M; Tovaryš F; Vymazal J
    World J Surg Oncol; 2012 Oct; 10():220. PubMed ID: 23095807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-irradiation of recurrent glioblastoma as part of a sequential multimodality treatment concept.
    Bräutigam E; Lampl C; Track C; Nieder C; Pichler J; Hammer J; Geinitz H
    Clin Transl Oncol; 2019 May; 21(5):582-587. PubMed ID: 30284233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent glioblastoma: Current patterns of care in an Australian population.
    Parakh S; Thursfield V; Cher L; Dally M; Drummond K; Murphy M; Rosenthal MA; Gan HK
    J Clin Neurosci; 2016 Feb; 24():78-82. PubMed ID: 26549675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
    Kanner AA; Wong ET; Villano JL; Ram Z;
    Semin Oncol; 2014 Oct; 41 Suppl 6():S25-34. PubMed ID: 25213871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of repeated surgery and adjuvant therapy on survival for patients with recurrent glioblastoma.
    De Bonis P; Fiorentino A; Anile C; Balducci M; Pompucci A; Chiesa S; Sica G; Lama G; Maira G; Mangiola A
    Clin Neurol Neurosurg; 2013 Jul; 115(7):883-6. PubMed ID: 22959214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
    J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence Pattern Analysis of Primary Glioblastoma.
    Rapp M; Baernreuther J; Turowski B; Steiger HJ; Sabel M; Kamp MA
    World Neurosurg; 2017 Jul; 103():733-740. PubMed ID: 28434963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients.
    Evans SM; Putt M; Yang XY; Lustig RA; Martinez-Lage M; Williams D; Desai A; Wolf R; Brem S; Koch CJ
    J Neurooncol; 2016 Apr; 127(2):391-400. PubMed ID: 26746692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.